Chargement en cours...
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DL...
Enregistré dans:
| Publié dans: | Blood Rev |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628697/ https://ncbi.nlm.nih.gov/pubmed/30528964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.blre.2018.11.002 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|